Biogen’s Hemophilia B drug Gets Green Signal in Canada
The latest statement by the Biogen Idec Inc. has revealed that the long-lasting hemophilia B drug, Alprolix, has gained green signal from Canada. The company stock closed at $347.04 in the US stock market on Thursday.
The main advantage of the drug is that it is administered only once a week or once in every 10 to 14 days to protect against bleeding episodes whereas earlier treatments have to be administered two or three times a week.
The officials reported that the single injection of the drug is capable of controlling 90% of bleeding in late-stage clinical trial.
Hemophilia B is a rare inherited disorder which affects about 4,000 people in United States and about 25,000 across the world. Hemophilia A is another more common form of the disease that affects about 20,000 people in the US. Biogen and Swedish Orphan Biovitrum AB are developing the Alprolix which is expected to be approved in US in later half of the year.
Biogen is working on another mission to develop a drug, Elocate, to treat hemophilia A, disease in which patients suffer reduced levels of coagulation factor VIII. The company said that the treatments for hemophilia B generate about $1 billion per year whereas the market for hemophilia A therapies generates revenue of about $6 billion.
The Cambridge based company added that the approval of the Alprolix will generate sales of $286 million by 2019 while Elocate can generate sales over $1.1 billion.
Recently-instated MPs spend increasing time at the...Read More
Celebrated Founding Director of the Center for...Read More
Although French President Emmanuel Macron vowed to...Read More